Adaptimmune Therapeutics (ADAP) Prices 20.5M ADS Offering at $11/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares
June 1, 2020 9:38 PM EDTPHILADELPHIA and OXFORDSHIRE, United Kingdom, June 01, 2020 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Adaptimmune)(Nasdaq: ADAP), a leader in cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 20,500,000 of its American Depositary Shares (ADSs) at a price to the public of $11.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,075,000 ADSs at the public offering price. The gross offering size for this offering is expected to be $225.5 million, excluding any exercise of the underwriters option to... More
